Hyponatremia (serum sodium < 135 mEq/L) is fundamentally a disorder of water balance—an excess of total body water relative to sodium—rather than a simple sodium deficit. The most effective diagnostic approach is to confirm true hypotonicity first, then categorize the hyponatremia according to the patient’s extracellular fluid (ECF) volume status: hypovolemic, euvolemic, or hypervolemic.
1. Core Concepts Before Volume Classification
Serum sodium reflects the ratio of exchangeable cations to total body water. Plasma osmolality must be measured first to exclude non-hypotonic states:
- Hypotonic Hyponatremia (True Hyponatremia): Plasma osmolality < 275–280 mOsm/kg. Confirms genuine intravascular dilution; proceed directly to volume status evaluation.
- Hypertonic Translocational Hyponatremia: Plasma osmolality > 295 mOsm/kg. Driven by osmotically active solutes restricted to the ECF—most commonly severe hyperglycemia (DKA/HHS) or intravenous mannitol. In insulin deficiency, glucose remains trapped in the ECF as an effective osmole, pulling intracellular water into the ECF and diluting serum sodium (1.6 mEq/L drop per 100 mg/dL glucose rise).
- Isotonic (Pseudo) Hyponatremia: Plasma osmolality 280–295 mOsm/kg. A laboratory artifact caused by marked hyperlipidemia or hyperproteinemia displacing the aqueous phase of plasma.
2. Hypovolemic Hyponatremia
In hypovolemic hyponatremia, both total body sodium and total body water are depleted, but sodium loss exceeds water loss. The decline in effective arterial blood volume (EABV) triggers non-osmotic ADH release, impairing renal free-water excretion and lowering serum sodium.
- Etiologies: Extrarenal losses (gastrointestinal, third-spacing, severe burns) vs. Renal losses (thiazide diuretics, mineralocorticoid deficiency, cerebral salt wasting).
- Diagnostic Key: Clinical volume depletion (orthostasis, tachycardia). Extrarenal loss shows U_Na < 20 mEq/L; renal loss shows U_Na > 20 mEq/L.
- Management: Restore intravascular volume with isotonic (0.9%) saline. Repletion removes the non-osmotic stimulus for ADH, allowing normal free-water clearance.
3. Euvolemic Hyponatremia
Euvolemic hyponatremia involves a modest increase in total body water with near-normal total body sodium and no clinical edema.
- Etiologies: SIADH (unregulated ADH secretion), hypothyroidism, glucocorticoid deficiency, primary polydipsia, medications (SSRIs, carbamazepine).
- SIADH Diagnostic Criteria: Low plasma osmolality, urine osmolality > 100 mOsm/kg, U_Na > 40 mEq/L, and clinically normal volume state without diuretic use.
- Management: Fluid restriction (800–1000 mL/day) is first-line. Refractory cases may require oral salt tablets with loop diuretics, urea, or vasopressin-receptor antagonists (vaptans).
4. Hypervolemic Hyponatremia
In hypervolemic hyponatremia, systemic total body sodium, chloride, glucose, and water are all elevated, resulting in expanded ECF volume (peripheral edema, ascites, pulmonary congestion). However, due to reduced cardiac output or splanchnic vasodilation, Effective Arterial Blood Volume (EABV) is severely reduced.
Detailed Pathophysiology:
- Tubular Solute Reabsorption vs. Translocational States: Unlike DKA/HHS where uncontrolled glucose remains trapped in the ECF as an effective osmole, hypervolemic states feature intact proximal tubular transport. Filtered glucose is completely reabsorbed via apical SGLT2/SGLT1 symporters in the proximal convoluted tubule and intracellularly metabolized.
- Altered Peritubular Starling Forces: Low EABV activates Angiotensin II, constricting efferent arterioles to preserve glomerular filtration. This increases the filtration fraction, producing high peritubular capillary oncotic pressure (π_pc) and low hydrostatic pressure (P_pc). This Starling force gradient drives massive bulk reabsorption of Na⁺, Cl⁻, HCO₃⁻, glucose, urea, and uric acid in the proximal tubule.
- Neurohumoral Triad & ADH Exaggeration: Sympathetic tone and RAAS maximize total body solute retention. Concurrently, carotid and aortic baroreceptors detect EABV depletion and trigger non-osmotic ADH secretion, inserting Aquaporin-2 (AQP2) channels into medullary collecting ducts. Free water retention disproportionately exceeds total solute retention (TBW ↑↑ > Total Solutes ↑), causing true dilutional hypotonic hyponatremia.
Diagnostic Indicators:
- U_Na < 20 mEq/L: Non-renal causes (CHF, Liver Cirrhosis, Nephrotic Syndrome) where intact tubules reabsorb maximal sodium due to low EABV.
- U_Na > 20 mEq/L: Renal causes (Acute Tubular Necrosis, End-Stage Kidney Disease) where intrinsic tubular damage prevents sodium reabsorption.
Management:
- Hyponatremia Direct Treatment: Free water restriction (800–1000 mL/day) to halt ongoing hemodilution, combined with loop diuretics to induce solute-rich diuresis and excrete free water.
- Underlying Disease Management: Dietary sodium restriction is indicated specifically to manage systemic volume overload and peripheral edema in underlying HF or cirrhosis.
5. Safety Correction Limits & Emergency Management
Severe Neurological Symptoms (Seizures, Coma):
- Administer 100–150 mL boluses of 3% hypertonic saline IV over 10–20 minutes.
- Repeat up to twice if severe symptoms persist, targeting an initial rise of 4–6 mEq/L in serum sodium.
- Discontinue hypertonic saline immediately once severe symptoms resolve.
24-Hour Limits (Preventing Osmotic Demyelination Syndrome – ODS):
- Standard Ceiling: Do not exceed a total rise of 8–10 mEq/L within any 24-hour period.
- High-Risk Ceiling: Limit correction to 6–8 mEq/L per 24 hours in patients with chronic alcoholism, severe malnutrition, advanced liver disease, or extreme baseline hyponatremia (< 105 mEq/L).
- Serial laboratory monitoring of serum sodium every 2–4 hours during active correction is mandatory.
6. Diagnostic Summary Matrix
| State | ECF Volume | UNa Threshold | Primary Etiologies | First-Line Therapy |
|---|---|---|---|---|
| Hypovolemic | Decreased | < 20 (Extrarenal) / > 20 (Renal) | GI Loss, Diuretics | Isotonic Saline (0.9% NS) |
| Euvolemic | Normal | > 40 (SIADH) | SIADH, Hypothyroidism | Fluid Restriction (800–1000 mL/d) |
| Hypervolemic | Increased | < 20 (Non-Renal) / > 20 (Renal) | CHF, Cirrhosis, CKD | Fluid Restriction + Loop Diuretics |
References
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, B. L., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Krantz, M. J., Lee, C. S., Martins, A. S., … Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012
Loscalzo, J., Fauci, A., Kasper, D., Hauser, S., Longo, D., & Jameson, J. L. (Eds.). (2022). Harrison’s principles of internal medicine (21st ed.). McGraw Hill.
Spasovski, G., Vanholder, R., Allolio, B., Annane, D., Ball, S., Bichet, D. G., Bolignano, D., Bou straina, A., Hoorn, E. J., Ichai, C., Joannidis, M., Soupart, A., Zietse, R., & Nagler, E. V. (2014). Clinical practice guideline on diagnosis and treatment of hyponatraemia. European Journal of Endocrinology, 170(3), G1–G47. https://doi.org/10.1530/EJE-13-1020
Sterns, R. H. (2015). Disorders of plasma sodium—causes, consequences, and correction. New England Journal of Medicine, 372(1), 55–65. https://doi.org/10.1056/NEJMra1404489
UpToDate. (2026). Diagnostic approach to hyponatremia in adults. Wolters Kluwer. Retrieved October 9, 2026, from https://www.uptodate.com
Verbalis, J. G., Goldsmith, S. R., Greenberg, A., Korzelius, C., Schrier, R. W., Sterns, R. H., & Thompson, C. J. (2013). Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. The American Journal of Medicine, 126(10 Suppl 1), S1–S42. https://doi.org/10.1016/j.amjmed.2013.07.006